Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Cancer. 2020 Jun 4;126(16):3788–3799. doi: 10.1002/cncr.32996

Fig. 6. Intermittent treatment schedules with osimertinib and trametinib combination (A) delay the emergence of osimertinib resistance in vivo (B) without enhancing toxicity (C).

Fig. 6.

A, Schema of intermittent treatment schedules tested: Schedule #1 involved 2-weeks osimertinib treatment followed by 2-weeks osimertinib and trametinib combination and Schedule #2 used 4-weeks osimertinib treatment followed by 2-weeks osimertinib and trametinib combination. These schedules were repeated until the end of the experiments. B and C, PC-9 xenografts in nude mice (6 mice/group) were treated with vehicle, osimertinib (15 mg/kg, og, once/day), trametinib (1 mg/kg, og, once/day) or the combination of osimertinib and trametinib given according to Schedule 1 or Schedule 2. Tumor sizes and mouse body weights were measured every three days and presented as means ± SEMs.